Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction.
Mi-Gil MoonIn Chang HwangWonsuk ChoiGoo-Yeong ChoYeonyee E YoonJun-Bean ParkSeung-Pyo LeeHyung-Kwan KimYong-Jin KimPublished in: ESC heart failure (2021)
In patients with HFrEF treated with sacubitril/valsartan, LV reverse remodelling reflects the treatment response and predicts the prognosis, whereas a lack of reverse remodelling indicates the lack of treatment benefits. Prediction and assessment of reverse remodelling may facilitate the selection of patients with greater benefits by sacubitril/valsartan.